Previously submitted to: JMIR Formative Research (no longer under consideration since Sep 19, 2023)
Date Submitted: Jul 11, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Efficacy of In-person and Telepractice Versions of Lee Silverman Voice Treatment on Dysarthria and Dysphagia in Adults with Cerebral Palsy
ABSTRACT
Background:
The Lee Silverman Voice Treatment (LSVT) has been demonstrated in multiple studies to improve the symptoms of dysphagia and dysarthria in Parkinson’s disease (PD) and other neurological disorders through the process of motor learning and intensive intervention.
Objective:
Efficacy of intensive voice therapy in improving speech and swallowing functions was investigated in adults with cerebral palsy (CP).
Methods:
Lee Silverman Voice Treatment (LSVT), a speech-behavior therapy, was performed on 16 subjects with CP (men:women= 9:7; mean age= 43.4±10.43 years) via an in-person program of an extended version of LSVT (LSVT-X), and a telepractice program of LSVT-X (LSVT e-LOUD-X). Maximum phonation time (MPT), voice intensity, diadochokinetic rate (DDK), Voice Handicap Index (VHI), swallowing-quality of life (SWAL-QOL), and Videofluoroscopic Dysphagia Scale (VDS) were analyzed before and after the LSVT treatments.
Results:
Speech function significantly improved in MPT (P = .006), voice intensity (P = .004), DDK /puh/ (P = .043), and DDK /puh-tuh-kuh/ (P = .031). Swallowing function significantly improved in pharyngeal phase on the VDS. Quality of life was also improved in physical (P = .003), emotional (P = .000), total score of VHI (P = .001), fear (P = .031), sleep (P = .013), fatigue (P = .003), and total score of SWAL-QOL (P = .019). Such improvements were observed in both LSVT-X and LSVT e-LOUD-X groups.
Conclusions:
LSVT-X and LSVT e-LOUD-X are equally effective in improving speech and swallowing functions and related quality of life measures in adults with CP. Clinical Trial: This study was approved by the Institutional Review Board (No. 4-2021-1009).
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.